Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

OTHER 420INDUSTRY 306NETWORK 45NIH 33OTHER_GOV 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Recurrence 2Vomiting 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hypersensitivity 1Disease Progression 1

Interventions

Dexamethasone 4Cyclophosphamide 3pomalidomide 2pegylated granulocyte colony-stimulating factor 2pegfilgrastim 2carfilzomib 2Etoposide 2Cytarabine 2Bortezomib 2fosaprepitant 1fludarabine 1daratumumab 1Zoledronic Acid 1Vaccination 1Tropisetron 1Thiotepa 1Renal Replacement Therapy 1Prednisone 1Pneumococcal Vaccines 1Olanzapine 1Melphalan 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Cyclosporine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER_GOV × Multiple Myeloma × Dexamethasone × Clear all
NCT07413809 2026-02-17

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
92 enrolled
Plasma cell

Multiple Myeloma

NCT04813653 2025-07-24

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

Tel-Aviv Sourasky Medical Center

Phase 1 Completed
3 enrolled
Plasma cell

Multiple Myeloma

NCT04065789 2022-01-27

KyDaR

Tel-Aviv Sourasky Medical Center

Phase 2 Completed
41 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03601624 2018-11-14

MM-POM-2018

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

Phase 2 Unknown
18 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡